Does Rallies show 13F holders for BRTX?

Yes. Rallies tracks hedge fund and 13F ownership data for BRTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BRTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BRTX. It does not provide personalized investment advice.

BRTX (BioRestorative Therapies, Inc. Common Stock (NV)) Stock Analysis - Hedge Fund Holdings

BioRestorative Therapies, Inc. Common Stock (NV) (BRTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BRTX trades at $0.17 with a market cap of $4.75M and a P/E ratio of -0.11. BRTX moved -7.84% today. Year to date, BRTX is -85.80%; over the trailing twelve months it is -89.15%. Its 52-week range spans $0.16 to $2.55. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces BRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BRTX stock?

Hedge funds tracked by Rallies that own BRTX include Renaissance Technologies. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioRestorative Therapies, Inc. Common Stock (NV).

BRTX Key Metrics

Key financial metrics for BRTX
Metric	Value
Price	$0.17
Market Cap	$4.75M
P/E Ratio	-0.11
EPS	$-1.58
Dividend Yield	0.00%
52-Week High	$2.55
52-Week Low	$0.16
Volume	83.17K
Avg Volume	0
Revenue (TTM)	$359.70K
Net Income	$-14.24M
Gross Margin	93.37%

Top Hedge Funds Holding BRTX

Renaissance Technologies holds 20.00K shares of BRTX, changed -19.55% as of Sep 30, 2024.

Latest BRTX News

BioRestorative Therapies Unveils MSC Exosome Proteomics from Cord, Adipose, Bone Marrow Enabling Targeted Regenerative, Aesthetic Applications — May 13, 2026
BioRestorative’s BRTX-100 Phase 2 Shows 52% ≥50% Pain and Function Gain in 25 Patients — May 7, 2026
BioRestorative to reveal Phase 2 lumbar disc safety data and exosome proteomics — Apr 30, 2026
BioRestorative Teams with 203 Creates to Launch BioX™ Platform Globally — Apr 7, 2026
BioRestorative Reports 75% Pain Relief at 52 Weeks, No Safety Events — Mar 30, 2026

Recent BRTX Insider Trades

Broadrick Dale sold 1.11K (~$1.76K) on Oct 28, 2024.
Silva Francisco bought 6.60K (~$8.25K) on Apr 9, 2024.
Silva Francisco bought 476 (~$537.88) on Apr 8, 2024.

BRTX Analyst Consensus

2 analysts cover BRTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about BRTX

Who owns BRTX stock?: Hedge funds tracked by Rallies that own BRTX include Renaissance Technologies. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioRestorative Therapies, Inc. Common Stock (NV).
Does Rallies show 13F holders for BRTX?: Yes. Rallies tracks hedge fund and 13F ownership data for BRTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BRTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BRTX. It does not provide personalized investment advice.